Gold treatment at an early stage of rheumatoid arthritis
- PMID: 103180
- DOI: 10.1093/rheumatology/xvii.suppl.94
Gold treatment at an early stage of rheumatoid arthritis
Abstract
The progression of erosive X-ray changes over a period of 5--6 years was evaluated in 39 patients exposed to a mean dose of 2030 mg aurothiomalate during the maintenance period. The cause for the low dose was the initial high incidence of side-effects. The progression of erosions was highest in patients with the low dose of gold in the initial stages of the disease. The best result in preventing development of erosions was achieved in patients with the high dose of gold in the early phase of the disease. It appears that gold treatment prevents the progression of the erosoins. The earlier the inception of treatment, the better the result.
Similar articles
-
Effect of gold on progression of erosions in rheumatoid arthritis. Better results with early treatment.Scand J Rheumatol. 1977;6(3):189-92. doi: 10.3109/03009747709095448. Scand J Rheumatol. 1977. PMID: 412248
-
[Radiologic healing phenomena in chronic polyarthritis treated with methotrexate or sodium aurothiomalate].Z Rheumatol. 1996 Jul-Aug;55(4):241-8. Z Rheumatol. 1996. PMID: 8967184 German.
-
Maintenance chrysotherapy in rheumatoid arthritis: a comparison of 2 dose schedules.Ann Rheum Dis. 1981 Jun;40(3):250-3. doi: 10.1136/ard.40.3.250. Ann Rheum Dis. 1981. PMID: 6787995 Free PMC article.
-
[Auranofin and aurothiomalate sodium: a comparative review (and II) Efficacy, tolerance and safety].Med Clin (Barc). 1985 Jun 8;85(2):73-9. Med Clin (Barc). 1985. PMID: 3160899 Review. Spanish. No abstract available.
-
Mechanism of action, pharmacology, clinical efficacy and side effects of auranofin. An orally administered organic gold compound for the treatment of rheumatoid arthritis.Pharmacotherapy. 1983 Sep-Oct;3(5):284-98. doi: 10.1002/j.1875-9114.1983.tb03277.x. Pharmacotherapy. 1983. PMID: 6417628 Review.
Cited by
-
Radiological evaluation of erosions: a quantitative method for assessing long-term remittive therapy in rheumatoid arthritis.Br J Clin Pharmacol. 1986;22 Suppl 2(Suppl 2):173S-182S. doi: 10.1111/j.1365-2125.1986.tb03001.x. Br J Clin Pharmacol. 1986. PMID: 3620278 Free PMC article.